Bevacizumab

Bevacizumab is on the WHO Model list of Essential Medicines and is approved for the treatment of multiple types of cancer.  Next to this indication, it is widely used off-label as an intravitreal injection for the successful treatment of this disorder for over a decade now. In fact it is an affordable and safe alternative for ranibizumab which is the only registered product for this indication. However, until now there is no pharmaceutical form of bevacizumab on the market in prefilled syringes, only as an intravenous injection for cancer treatment. To prevent the safety risks associated with the dispensing of bevacizumab, UCAB explores the possibilities to develop a pharmaceutical presentation of a bevacizumab biosimilar in a prefilled syringe, designed and authorized for intravitreal injections in LMICs.